Try our corporate solution for free!
(212) 419-8286

AbbVie's R&D expenditures as revenue share 2012-2020

This statistic illustrates the expenditure of AbbVie on research and development as a percentage of revenue from 2012 to 2020. In 2020, AbbVie spent some 14 percent of its revenue on research and development. Abbot was a U.S.-based global pharmaceutical and healthcare products company, headquartered in Chicago, Illinois. In January 2013, Abbott was separated into two companies: Abbott Laboratories and AbbVie. Abbott Laboratories is now specialized on medical products, while AbbVie is responsible for research-based pharmaceuticals. On May 8, 2020, AbbVie completed the acquisition of Allergan plc.

AbbVie's research and development spending as a share of revenue from 2012 to 2020

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in

Release date




Survey time period

2012 to 2020

Supplementary notes

This statistic was assembled from several of Abbvie's annual reports.
* Research and development expenses in 2018 increased from 2017 principally due to a $5.1 billion intangible asset impairment charge related to IPR&D acquired as part of the 2016 Stemcentrx acquisition following the decision to stop enrollment in the TAHOE trial.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.